Breaking

WHO Recommends Two Antibiotics for COVID-19 Treatment

The recommendations are based on evidence from ongoing trials that show the two antibodies reduce the risk of hospitalisation and duration in symptoms if those at the highest risk of acquiring severe disease for instance unvaccinated persons, the old or immunosuppressed patients.
The World Health Organisation has approved the use of Casirivimad and Imdevimab, both antibiotics for COVID-19 treatment. The health agency recommends that the drugs be used on patients with non-severe COVID-19 but are at a high risk of hospitalisation and patients with symptoms of severe or critical forms of the disease who test negative for the presence of the virus(seronegative).

The recommendations are based on evidence from ongoing trials that show the two antibodies reduce the risk of hospitalisation and duration in symptoms if those at the highest risk of acquiring severe disease for instance unvaccinated persons, the old or immunosuppressed patients.  

Data from the studies show that when used in combination, the anti-bodies get attached to the SARS-CoV-2 virus spike protein. This affects the virus's ability to infect cells. This is the third treatment recommendation for COVID-19 that the WHO has made. Earlier on, the health agency approved Dexamethasone and Tocilizumab or Sarilumab.

Keywords